13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
29 檔
59.5%
As reported in its official Q3 2024 Form 13F filing, BML Capital Management, LLC's tracked investment portfolio stood at $175.7M with 29 total positions.
During Q3 2024, BML Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SGOV, TIL, AVIR) accounted for 59.5% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 16.00% | — | — | |
| 2 | TIL | Instil Bio Inc | Stock-Other | 13.27% | -0.59% | -14.34% | |
| 3 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 13.11% | -5.98% | +4.30% | |
| 4 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 9.64% | +1.74% | +9.72% | |
| 5 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 9.45% | — | -12.50% | |
| 6 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 9.37% | — | +15.36% | |
| 7 | TECX | Tectonic Therapeutic Inc | Stock-Other | 3.78% | — | -54.56% | |
| 8 | ANTX | An2 Therapeutics Inc | Stock-Other | 3.62% | — | — | |
| 9 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 3.46% | — | +29.38% | |
| 10 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 3.14% | -4.54% | +62.06% | |
| 11 | 698 | Achilles Therapeutics Pl-adr | Stock-Other | 2.46% | — | +555.82% | |
| 12 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 2.42% | — | — | |
| 13 | CNTB | Connect Biopharma Holdings Limited | Stock-Other | 1.77% | — | +2.45% | |
| 14 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.48% | -0.18% | +28.97% | |
| 15 | ASTC | Astrotech CORP | Stock-Other | 1.04% | — | — | |
| 16 | MIST | Milestone Pharmaceuticals In | Stock-Other | 1.02% | — | +3.01% | |
| 17 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.84% | — | -6.13% | |
| 18 | ✓ | Ikena Oncology Inc | Stock-Other | 0.74% | — | +23.61% | |
| 19 | VNDA | Vanda Pharmaceuticals Inc | Stock-Other | 0.63% | — | -42.63% | |
| 20 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 21 | ✓ | Stock-Other | 0.41% | — | — | ||
| 22 | CALC | Calcimedica Inc | Stock-Other | 0.40% | — | -4.07% | |
| 23 | ✓ | Stock-Other | 0.29% | — | — | ||
| 24 | TLIS | Talis Biomedical CORP | Stock-Other | 0.27% | — | +481.85% | |
| 25 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 26 | FBRX | Forte Biosciences Inc | Stock-Other | 0.23% | — | — | |
| 27 | NXTCEUR | Nextcure Inc | Stock-Other | 0.22% | — | — | |
| 28 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.15% | — | — | |
| 29 | ✓ | Hillevax Inc | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 29 disclosed positions in Q3 2024.
During Q3 2024, BML Capital Management, LLC's top holdings by market value included SGOV (16.0%)、TIL (13.3%)、AVIR (13.1%). The largest single position, SGOV, represented 16.0% of total portfolio value.
In Q3 2024, BML Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.